[go: up one dir, main page]

WO1991016921A1 - Procede et composition destines au traitement du cancer - Google Patents

Procede et composition destines au traitement du cancer Download PDF

Info

Publication number
WO1991016921A1
WO1991016921A1 PCT/GB1991/000715 GB9100715W WO9116921A1 WO 1991016921 A1 WO1991016921 A1 WO 1991016921A1 GB 9100715 W GB9100715 W GB 9100715W WO 9116921 A1 WO9116921 A1 WO 9116921A1
Authority
WO
WIPO (PCT)
Prior art keywords
hormone
pituitary
cancer
pituitary hormone
tumour cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/000715
Other languages
English (en)
Inventor
John Robert Stephenson
Peter Morgan Sutton
Jack Melling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health Laboratory Service Board
Public Health England
Original Assignee
Health Protection Agency
Public Health Laboratory Service Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency, Public Health Laboratory Service Board filed Critical Health Protection Agency
Publication of WO1991016921A1 publication Critical patent/WO1991016921A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Definitions

  • This invention relates to a method and composition for the treatment of cancer.
  • lymphocytes i.e. cell mediated immunity
  • lymphocytes from a patient with a malignant lung tumour can kill pulmonary tumour cells from other patients, but not tumour cells from other tissues. This target specificity could explain some of the original conflicting data on the ability of lymphocytes
  • the present invention is based upon the appreciation that stimulation of the immune system by pitutary hormones has utility in the prevention and treatment of cancer.
  • a method of treating or preventing cancer in a subject which comprises administering a pituitary hormone.
  • the invention further provides the use of a pituitary hormone in the manufacture of a pharmaceutical composition for producing an anti-cancer effect.
  • the pituitary hormone is a pituitary glycoprotein hormone, most preferably pituitary growth hormone (HGH) .
  • HGH pituitary growth hormone
  • Other examples of pituitary hormones include luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone and prolactin.
  • Pituitary growth hormone used in accordance with the invention may be characterised in terms of biological activity.
  • pituitary growth hormone may be defined as a polypeptide capable of stimulating long bone growth and releasing somatomedin. Such activity may be detected by the methods described in Marx et al. (19* ⁇ 2), Endocrinology, 30, 1. and Greenspan et al. (19* ⁇ 9) . Endocrinology, 45, -455-
  • pituitary growth hormone may be defined in terms of its antigenic reaction with
  • the anti-cancer effect obtainable in accordance with the invention may be used in the' treatment of cancer itself and also in the prevention of cancer and in the treatment of pre-cancerous conditions, including benign tumours.
  • pituitary hormones in accordance with the invention act by exerting an immunostimulant effect, which enabled the body's immune defence mechanisms to reject cancer cells.
  • the pituitary glycoprotein hormone may be administered by any convenient means.
  • it may be administered orally or parenterally.
  • Parenteral modes of administration include administration by injection intravenously, intramuscularly, subcutaneously, intrathecally or into a body cavity, e.g. intraperitoneally or intrapleurally.
  • hormone is administered orally for systemic administration, in order to avoid inactivation in the stomach, it is
  • SUBSTITUTESHEET preferably administered in the form of an enteric-coated tablet or pill, or in the form of a capsule resistant to degradation in the stomach.
  • rectal administration in the form of a suppository, vaginally as a pessary, in the form of an aerosol as in a nasal spray or as eye drops.
  • the hormone may be administered in conjunction with an innoculation regime designed to induce the formation of antibodies against cancer cells.
  • an innoculation regime may involve injection of inactivated (killed) cancer cells or of antigens derived from cancer cells.
  • the pituitary hormone may be administered prior to, simultaneously with or subsequent to the administration of the inactivated (killed) cancer cells or antigen.
  • the hormone and inactivated (killed) cancer cells or antigen comprise a single composition adapted for parenteral administration.
  • the pharmaceutical preparations according to the invention thus may comprise a single composition containing both the antigen or inactivated (killed) cancer cells and the pituitary hormone or these two components may be present in the form of a kit comprising separate aliquots thereof.
  • the pituitary hormone is advantageously administered in a form which encourages localised retention.
  • Pharmaceutical conditions embodying such forms (whether or not they additionally comprise one or more of the aforementioned antigens or inactivated (killed) cancer cells) form a further aspect of the invention.
  • an injectable pharmaceutical composition for use in conjunction with an antigenic component of an anti-cancer vaccine, said pharmaceutical composition comprising a pituitary hormone and a pharmaceutically acceptable carrier, said carrier (or an optional additional component of the composition) being selected so as to promote localised retention of the pituitary hormone at or adjacent to the injection sites.
  • said composition comprises an adjuvant such as, for example, aluminium hydroxide.
  • a suitable dose of the of the pituitary hormone is dependent on the mode of application, and the identity of the hormone.
  • Pituitary hormone may be used in accordance with the present invention in combination therapies together with other therapeutic agents having an anticancer activity.
  • the following regimes illustrates the invention:
  • Patients with an inherited predisposition to cancers such as xeroderma pigmentosum and some lymphomas may be treated by injecting HGH into the lesions or removing some of the tumour and reinjecting the tumour along with HGH.
  • Patients who have had recent surgery for say example breast cancer, may be treated with HGH as part of their follow-up chemotherapy and their survival and regression rates compared to a control group.
  • pituitary hormones via the cell-mediated immune response (rather than by the humoral or antibody response).
  • a mode of administration of pituitary hormones which maximises such a response is preferred, i.e. one in which the pituitary hormone is administered in a form which encourages localised retention of the hormone and/or one or more of the aforementioned antigens or inactivated (killed) cancer cells inactivated (killed) cancer cells after injection.
  • Such forms include injectable compositions which include known adjuvants such as, for example, aluminium hydroxide.
  • compositions may be produced in accordance with the invention comprising both the pituitary hormone and the antigen in a single composition.
  • compositions produced in accordance with the invention may comprise conventional pharmaceutically acceptable diluents or carriers.
  • typical injectable solutions will comprise sterile pyrogen-free media, e.g. normal saline and optionally include buffering agents, stabilising agents and preservatives.
  • conventional enteric coatings may be used.
  • Tablets and pills may include conventional excipients such as, for example, lactose, starch and magnesium stearate while suppositories will include excipients such as waxes and glycerol.
  • compositions according to the invention are topical compositions for treating cancer .
  • Such compositions may comprise a pituitary hormone and an excipient adapted for topical application.
  • Such compositions may for example be in the form of creams, ointments, lotions, solutions or gels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à un procédé de production d'un effet anticancéreux, qui comprend l'administration d'une hormone pituitaire, en particulier d'une hormone pituitaire de glycoprotéine telle qu'une hormone de croissance pituitaire. De plus, l'invention se rapporte à l'utilisation d'une hormone pituitaire dans la fabrication d'une composition pharmaceutique s'utilisant dans le traitement ou la prévention du cancer chez un patient.
PCT/GB1991/000715 1990-05-04 1991-05-03 Procede et composition destines au traitement du cancer Ceased WO1991016921A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909010058A GB9010058D0 (en) 1990-05-04 1990-05-04 Method and composition for the treatment of cancer
GB9010058.7 1990-05-04

Publications (1)

Publication Number Publication Date
WO1991016921A1 true WO1991016921A1 (fr) 1991-11-14

Family

ID=10675480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000715 Ceased WO1991016921A1 (fr) 1990-05-04 1991-05-03 Procede et composition destines au traitement du cancer

Country Status (3)

Country Link
AU (1) AU7770991A (fr)
GB (1) GB9010058D0 (fr)
WO (1) WO1991016921A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
WO1996004008A1 (fr) * 1994-08-05 1996-02-15 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Traitement du cancer par la gonadotrophine chorionique humaine
WO1997014428A1 (fr) * 1995-10-16 1997-04-24 Applied Research Systems Utilisation de gonadotrophine chorionique humaine dans le traitement du sarcome de kaposi
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
WO2001024822A3 (fr) * 1999-10-01 2001-12-20 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
WO2007009383A1 (fr) * 2005-07-19 2007-01-25 Genescience Pharmaceuticals Co., Ltd. Suppositoire rectal de proteine et son procede de preparation et son utilisation
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004241A1 (fr) * 1985-01-18 1986-07-31 John Mcmichael Procedes et compositions immunotherapeutiques utilisant des antigenes caracteristiques de neoplasmes de nature maligne
WO1987003487A1 (fr) * 1985-12-09 1987-06-18 John Mcmichael Procedes et materiaux pour l'allegement de symptomes de la douleur associes a une neoplasie maligne
WO1990002559A1 (fr) * 1988-09-15 1990-03-22 Public Health Laboratory Service Board Composition pharmaceutique permettant de provoquer un effet immunostimulant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004241A1 (fr) * 1985-01-18 1986-07-31 John Mcmichael Procedes et compositions immunotherapeutiques utilisant des antigenes caracteristiques de neoplasmes de nature maligne
WO1987003487A1 (fr) * 1985-12-09 1987-06-18 John Mcmichael Procedes et materiaux pour l'allegement de symptomes de la douleur associes a une neoplasie maligne
WO1990002559A1 (fr) * 1988-09-15 1990-03-22 Public Health Laboratory Service Board Composition pharmaceutique permettant de provoquer un effet immunostimulant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, volume 82, no. 1 6th January 1975, (Columbus, Ohio, US) W. Neish: "Growth hormone.. Effect on Rd/3 rat sarcoma growth", see page 53 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
WO1996004008A1 (fr) * 1994-08-05 1996-02-15 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Traitement du cancer par la gonadotrophine chorionique humaine
US5677275A (en) * 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US5877148A (en) * 1994-08-05 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
WO1997014428A1 (fr) * 1995-10-16 1997-04-24 Applied Research Systems Utilisation de gonadotrophine chorionique humaine dans le traitement du sarcome de kaposi
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6699656B2 (en) 1996-06-24 2004-03-02 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6620416B1 (en) 1997-06-24 2003-09-16 University Of Maryland Biotechnology Institute Method for treating HIV
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6699834B1 (en) 1997-06-24 2004-03-02 University Of Maryland Biotechnology Institute Method for treating cancer
US6805882B1 (en) 1997-06-24 2004-10-19 University Of Maryland Biotechnology Institute Therapeutic fractions of sources of HCG
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US9175077B2 (en) 1999-08-06 2015-11-03 Nobel Biosciences Llc Nucleic acids encoding biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
WO2001024822A3 (fr) * 1999-10-01 2001-12-20 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene
US8277815B2 (en) 1999-10-01 2012-10-02 Intercell Ag Pharmaceutical composition comprising an antigen
WO2007009383A1 (fr) * 2005-07-19 2007-01-25 Genescience Pharmaceuticals Co., Ltd. Suppositoire rectal de proteine et son procede de preparation et son utilisation

Also Published As

Publication number Publication date
GB9010058D0 (en) 1990-06-27
AU7770991A (en) 1991-11-27

Similar Documents

Publication Publication Date Title
Rees et al. Increase in incidence of childhood empyema in West Midlands, UK
JP2813017B2 (ja) 癌療法の副作用の減少方法
EP0249629B1 (fr) Procedes et materiaux pour l'allegement de symptomes de la douleur associes a une neoplasie maligne
WO1991016921A1 (fr) Procede et composition destines au traitement du cancer
US5061488A (en) Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096707A (en) Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
CN111714620A (zh) Il-12在术后抗肿瘤方面的应用
Yefenof et al. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K
JP2001508764A (ja) 免疫原性ｔｌｐ組成物
RU2003330C1 (ru) Способ лечени рака молочной железы
RU2210390C2 (ru) Способ лечения злокачественных опухолей
US20060159658A1 (en) Methods of treating disease with glycosylated interferon
SU1706624A1 (ru) Способ лечени опиумно-морфинных наркоманий
Del Giacco et al. Combination Chemotherapy and Cytokines in the Treatment of Advanced Primary Lung Cancer: Controlled Clinical Trial Three Year Results
Martin The necessity for combined modalities in cancer therapy
TWI882612B (zh) 藥物組合及其應用
Greiner et al. Urticaria associated with a small cell carcinoma of the lung
Li Research of immunotherapy in pancreatic cancer
RU2271831C1 (ru) Способ лечения онкологических заболеваний
Penney et al. Tucaresol-Cyclophosphamide Combination Therapy: Proposal for a Safe
CN110151987B (zh) 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途
Cheng et al. A preliminary study of intralesional, intralymph node, intravenous and intraperitoneal Corynebacterium parvum treatments in patients with advanced cancer
Helander et al. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
Roberts Immunotherapy in the treatment of cancer
Mekori et al. Immune investigations and therapy in patients with advanced lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

NENP Non-entry into the national phase

Ref country code: CA